Drugs / Atazanavir
Atazanavir
also known as
ATV · Reyataz · ATZ · atazanavir/r · Atazanavir Sulphate · BMS 232632 · Atazanavir (as sulfate) · atazanavir (Reyataz, ATV) · +12 more
Other / unclassified targets UGT1A1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed HIV infectious disease 1 milestone | |||||
| Filed | US (FDA) | — | HIV infectious disease | — | “In April, the company announced the submission of an NDA to the FDA for a fixed-dose combination of atazanavir sulfate” bms.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (9) | US (FDA) | REYATAZ | — | 2004-07-06 – 2017-05-23 | fda.gov ↗ |
| Approved | EU (EMA) | Reyataz | — | 2004-03-01 | europa.eu ↗ |
| Approved | US (FDA) | REYATAZ | — | 2003-06-20 | fda.gov ↗ |
Trials 107 · started per year
today
US approved 2003
EU approved 2004
2
1
3
4
2
6
12
8
6
7
9
5
9
7
1
5
8
1
1
6
1
2
1
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 122 trials | ||||||
| Phase 1 | NCT05236738 | May → Jul 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04263350 | Feb → Nov 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04184869 | Aug 2019 → Dec 2022 | cancer, hematopoietic and lymphoid cell neoplasm | Acrotech Biopharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02589158 | Nov 2015 → Mar 2016 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT02565888 | Nov 2015 → Jan 2016 | HIV infectious disease, hepatitis C virus infection | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02307656 | Dec 2014 → Sep 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02034838 | Jan → Nov 2014 | HIV infectious disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01818856 | Dec 2012 → Apr 2013 | HIV infectious disease, chronic hepatitis C virus infection | Hospitales Universitarios Virgen del Rocío | Completed | No outcome recorded |
| Phase 1 | NCT01421355 | May 2012 → Feb 2014 | type 1 diabetes mellitus | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01592305 | May → Jun 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01591850 | Sep → Nov 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01368783 | Jun 2011 → ? | — | Asan Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT01073761 | Apr → Jun 2010 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT00883935 | Apr → Jun 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00878306 | Nov 2008 → Apr 2013 | HIV infectious disease, substance abuse | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00357604 | Jul → Nov 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00326716 | Jun 2006 → Jan 2009 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00162149 | Oct 2005 → Jul 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00307502 | Jan 2005 → Dec 2009 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02253836 | Jan → Jul 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00135434 | Sep 2004 → Jun 2005 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02257008 | Mar → Dec 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01565889 | Mar 2012 → Aug 2013 | HIV infectious disease, hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT00260078 | Feb 2006 → Apr 2009 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT00006604 | Nov 2000 → Oct 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 215 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04459286 | Oct 2020 → May 2021 | COVID-19 | Obafemi Awolowo University | Terminated | Missed primary |
| Phase 2 | NCT02542852 | Sep 2015 → Jun 2016 | HIV infectious disease | Castagna Antonella | Completed | No outcome recorded |
| Phase 2 | NCT02566707 | Aug 2015 → Dec 2016 | HIV infectious disease | Radboud University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02386098 | Jul 2015 → Jun 2017 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT02473328 | Jun 2015 → Dec 2017 | HIV infectious disease | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | Completed | No outcome recorded |
| Phase 2 | NCT01903031 | Dec 2014 → Oct 2016 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | Met primary |
| Phase 2 | NCT01656109 | Jul 2011 → Feb 2013 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 2 | NCT00896051 | Aug 2009 → Apr 2012 | AIDS | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00820118 | May 2009 → May 2012 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00696722 | Jun 2008 → Mar 2009 | type 2 diabetes mellitus | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00528060 | Jan → Nov 2008 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2 | NCT00122577 | Mar 2002 → Jul 2004 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Terminated | No outcome recorded |
| Phase 2 | NCT00004584 | Dec 1999 → Jan 2002 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00002240 | Mar 1999 → Dec 2001 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00007202 | ? → Oct 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/35 trials · 2 missed | ||||||
| Phase 2/3 | NCT04452565 | Jun 2022 → Dec 2023 | severe acute respiratory syndrome | Biomed Industries, Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT04468087 | Feb → Aug 2021 | COVID-19 | Hospital do Coracao | Completed | Missed primary |
| Phase 2/3 | NCT04121195 | Oct 2020 → May 2022 | HIV infectious disease, tuberculosis | University of Liverpool | Completed | No outcome recorded |
| Phase 2/3 | NCT02016924 | Jan 2014 → Jun 2025 overdue | AIDS | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00624195 | Mar 2007 → Feb 2012 | HIV infectious disease | University of California, San Diego | Completed | Missed primary |
| Phase 320 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT04022967 | Sep 2020 → Feb 2025 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 3 | NCT03708861 | Jan 2016 → Dec 2017 | HIV infectious disease | University of Turin, Italy | Withdrawn | No outcome recorded |
| Phase 3 | NCT01605084 | Jun 2012 → Aug 2014 | HIV infectious disease | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 3 | NCT01255371 | Mar 2012 → May 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Withdrawn | No outcome recorded |
| Phase 3 | NCT01335698 | May 2011 → Sep 2014 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01099579 | Oct 2010 → Oct 2012 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01511809 | Sep 2010 → Jul 2013 | HIV infectious disease | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 3 | NCT00811954 | May 2009 → Jun 2013 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 3 | NCT00440947 | Mar 2007 → Jul 2010 | HIV infectious disease | ViiV Healthcare | Completed | Met primary |
| Phase 3 | NCT00337467 | Jun 2006 → May 2008 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00280969 | Sep 2005 → Sep 2009 | HIV infectious disease | International Medical Center of Japan | Completed | No outcome recorded |
| Phase 3 | NCT00118898 | Sep 2005 → Nov 2009 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 3 | NCT00225017 | Jun 2005 → Jun 2008 | HIV infectious disease, hyperlipidemia | Northwestern University | Completed | No outcome recorded |
| Phase 3 | NCT00074581 | Feb 2005 → May 2015 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
| Phase 3 | NCT00160329 | Jan 2004 → Apr 2007 | HIV infectious disease, hyperlipidemia | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT01003990 | Oct 2002 → Feb 2016 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00028067 | Aug 2001 → Apr 2002 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 3 | NCT00013897 | Feb 2001 → Apr 2003 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00028301 | Feb 2001 → Sep 2003 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00013520 | ? → Jun 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 432 trials · 3 met primary · 7 missed | ||||||
| Phase 4 | NCT06337032 | Aug 2024 → Mar 2034 expected | HIV infectious disease | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT04311957 | Sep 2020 → May 2022 | HIV infectious disease | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | Unknown | Met primary |
| Phase 4 | NCT02513147 | Jun 2015 → Nov 2016 | — | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02246998 | Dec 2014 → Jan 2016 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01367236 | Jan 2013 → Oct 2015 | HIV infectious disease, cognitive disorder | Imperial College London | Completed | Missed primary |
| Phase 4 | NCT01602822 | Feb → May 2012 | HIV infectious disease | Kenneth H. Mayer, MD | Terminated | No outcome recorded |
| Phase 4 | NCT01351740 | Jul 2011 → Jan 2015 | HIV infectious disease | University of British Columbia | Completed | Missed primary |
| Phase 4 | NCT01159223 | May 2011 → Dec 2014 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | Met primary |
| Phase 4 | NCT01274780 | May 2011 → May 2013 | — | Juan A. Arnaiz | Completed | Missed primary |
| Phase 4 | NCT01928407 | Feb → Mar 2011 | HIV infectious disease, immunodeficiency-related disorder | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Completed | Missed primary |
| Phase 4 | NCT01232127 | Feb → Jun 2011 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01194856 | Oct 2010 → Dec 2011 | HIV infectious disease, mitochondrial disease | The Cleveland Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00955968 | Jan 2010 → Aug 2016 | HIV infectious disease | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Completed | No outcome recorded |
| Phase 4 | NCT00931801 | Dec 2009 → Feb 2012 | HIV infectious disease | Community Research Initiative of New England | Completed | No outcome recorded |
| Phase 4 | NCT00940771 | Aug 2009 → Oct 2013 | HIV infectious disease | Phoenix Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00885482 | May 2009 → May 2010 | HIV infectious disease | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 4 | NCT00869960 | Mar 2009 → Dec 2010 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT00757783 | Oct 2008 → Aug 2009 | HIV infectious disease | Tibotec, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00756730 | Sep 2008 → Jun 2011 | HIV infectious disease | Community Research Initiative of New England | Completed | No outcome recorded |
| Phase 4 | NCT00751153 | Mar 2008 → Oct 2009 | HIV infectious disease | Peter J. Ruane, M.D., Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT00532168 | Sep 2007 → Dec 2012 | HIV infectious disease | Juan A. Arnaiz | Completed | Missed primary |
| Phase 4 | NCT00420355 | Apr → Oct 2007 | HIV infectious disease | University of Oklahoma | Terminated | No outcome recorded |
| Phase 4 | NCT00355719 | Jan 2007 → Feb 2008 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00426296 | Aug 2006 → ? | HIV infectious disease, lipodystrophy | Clinical Alliance for Research & Education - Infectious Diseases, LLC. | Unknown | No outcome recorded |
| Phase 4 | NCT00389402 | Jul 2006 → Jul 2008 | HIV infectious disease | International Antiviral Therapy Evaluation Center | Completed | No outcome recorded |
| Phase 4 | NCT00385645 | May 2006 → Aug 2009 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | Missed primary |
| Phase 4 | NCT00207142 | Nov 2005 → Aug 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00224445 | Sep 2005 → Jan 2007 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00312754 | Jun 2005 → Apr 2007 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00084136 | May 2005 → May 2010 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | Mixed |
| Phase 4 | NCT00447070 | Aug 2004 → May 2006 | HIV infectious disease, hyperlipidemia | Foundation for Cardiovascular Research, Zurich | Completed | Missed primary |
| Phase 4 | NCT00082394 | Apr 2004 → Mar 2006 | HIV infectious disease | GlaxoSmithKline | Completed | Met primary |
| Phase not applicable9 trials | ||||||
| — | NCT05680792 | Sep 2020 → Jan 2023 | — | Obafemi Awolowo University | Completed | No outcome recorded |
| — | NCT02652793 | Nov 2015 → Nov 2018 | HIV infectious disease | Judit Pich | Completed | No outcome recorded |
| — | NCT00814879 | May 2009 → May 2013 | AIDS | Yale University | Completed | No outcome recorded |
| — | NCT00884793 | Sep 2008 → Dec 2009 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT00084019 | Jul 2004 → May 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00525239 | Mar 2004 → Dec 2010 | HIV infectious disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Unknown | No outcome recorded |
| — | NCT00720590 | Nov 2003 → Sep 2006 | — | Indiana University | Completed | No outcome recorded |
| — | NCT00028314 | Mar 2002 → Mar 2005 | HIV wasting syndrome, lipodystrophy | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00096850 | ? → Dec 2007 | HIV infectious disease, tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00046345 | May 2002 → Jul 2003 | HIV infectious disease | Bristol-Myers Squibb | No longer available | No outcome recorded |
| Comparator or background therapy81 trials | ||||||
| Phase 1 | NCT02556268 Background | Feb → Dec 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01759875 Comparator | Jan 2013 → Jan 2014 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01404572 Comparator | Aug → Sep 2011 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01458769 Comparator | Dec 2010 → Apr 2011 | — | Concert Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00833482 Comparator | Sep 2009 → Jul 2010 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00646776 Comparator | Apr → Aug 2008 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00518297 Comparator | Aug → Dec 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00362726 Comparator | Sep → Nov 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00357188 Comparator | Jul → Sep 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00357721 Comparator | Jun → Sep 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00357240 Comparator | Jun → Aug 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00365339 Comparator | Apr → Jun 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT00411957 Comparator | Jan 2007 → Jan 2008 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 2 | NCT06338826 Background | Feb 2025 → Sep 2027 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02116660 Comparator | Sep 2014 → Jul 2017 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01803074 Background | Apr 2013 → Nov 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01384734 Comparator | Jul 2011 → Feb 2013 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00943540 Background | Jul 2009 → Dec 2010 | HIV infectious disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00892437 Background | May → Dec 2009 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00827112 Background | Mar 2009 → Jul 2010 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00665847 Background | Nov 2008 → May 2011 | — | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00768989 Comparator | Nov 2008 → Jan 2010 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00122603 Background | Dec 2005 → Aug 2007 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2/3 | NCT02285114 Background | Jan 2015 → Nov 2019 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01923311 Background | Aug 2013 → Nov 2017 | AIDS | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT03019783 Comparator | Dec 2011 → Jun 2015 | HIV infectious disease | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT03256422 Background | Sep 2017 → Aug 2019 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02616783 Comparator | Dec 2015 → Feb 2018 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT02603107 Background | Nov 2015 → May 2017 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT02605954 Comparator | Nov 2015 → Jun 2017 | HIV infectious disease | Gilead Sciences | Completed | Missed primary |
| Phase 3 | NCT02469246 Background | Jun 2015 → Dec 2017 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT02397096 Background | Jun 2015 → Feb 2018 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT02269917 Comparator | Mar 2015 → Feb 2017 | HIV infectious disease | Janssen R&D Ireland | Completed | Met primary |
| Phase 3 | NCT02302547 Comparator | Dec 2014 → Aug 2017 | HIV infectious disease | University Hospital, Tours | Completed | No outcome recorded |
| Phase 3 | NCT02157311 Background | Jul 2014 → Jan 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02121795 Background | May 2014 → Aug 2015 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT02155101 Comparator | May 2014 → Jun 2016 | HIV infectious disease | University of Liverpool | Completed | No outcome recorded |
| Phase 3 | NCT01967940 Background | Oct 2013 → May 2015 | AIDS | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT01910402 Comparator | Aug 2013 → Sep 2015 | HIV infectious disease | ViiV Healthcare | Completed | Met primary |
| Phase 3 | NCT01815736 Comparator | Mar 2013 → Mar 2015 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT01620944 Background | Jul 2012 → Jan 2013 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT01475838 Comparator | Nov 2011 → Nov 2013 | AIDS | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT01363011 Background | May 2011 → Jan 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01252940 Background | Nov 2010 → Jan 2012 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01106586 Comparator | Apr 2010 → Sep 2011 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT01108510 Background | Apr 2010 → Nov 2011 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT00874523 Comparator | Jul 2009 → Jul 2011 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 3 | NCT00708162 Background | Jul 2008 → Dec 2010 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT00389207 Comparator | Oct 2006 → Feb 2011 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00272779 Comparator | Nov 2005 → Jun 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00135395 Comparator | May 2004 → Feb 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00120393 Comparator | Jan 2004 → May 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00067782 Comparator | Dec 2002 → Mar 2005 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00035932 Comparator | Nov 2001 → Jul 2003 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01902186 Background | Sep 2014 → Dec 2016 | HIV infectious disease | Giovanni Di Perri | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01829802 Background | May 2014 → Oct 2017 | HIV infectious disease | Pedro Cahn | Unknown | No outcome recorded |
| Phase 4 | NCT01599364 Background | Apr 2014 → Apr 2016 | HIV infectious disease | Catholic University of the Sacred Heart | Completed | Met primary |
| Phase 4 | NCT01691794 Comparator | Nov 2012 → Oct 2014 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01637259 Comparator | Jun 2012 → Dec 2015 | HIV infectious disease, proteinuria | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01332227 Background | Oct 2011 → Sep 2013 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01307488 Background | Sep 2011 → Apr 2014 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | Met primary |
| Phase 4 | NCT01225705 Comparator | Oct 2010 → Aug 2012 | HIV infectious disease, hepatitis C virus infection | University Hospital, Bonn | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01105611 Comparator | Aug 2010 → Dec 2012 | HIV infectious disease, hepatitis C virus infection | St. James's Hospital, Ireland | Unknown | No outcome recorded |
| Phase 4 | NCT01102972 Comparator | Apr 2010 → Jun 2012 | HIV infectious disease | ViiV Healthcare | Completed | Met primary |
| Phase 4 | NCT00762892 Comparator | Jan 2009 → Dec 2012 | HIV infectious disease | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT00544128 Comparator | Oct 2007 → Feb 2012 | HIV infectious disease | International Medical Center of Japan | Completed | No outcome recorded |
| Phase 4 | NCT00552240 Comparator | Sep 2007 → Mar 2010 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00540137 Comparator | Jul 2007 → Dec 2012 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT00335322 Comparator | Feb 2007 → Mar 2011 | HIV infectious disease | Kirby Institute | Completed | Met primary |
| Phase 4 | NCT00384904 Comparator | Dec 2006 → Dec 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01388543 Comparator | Sep 2006 → Jun 2008 | HIV infectious disease | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT00135356 Comparator | Jul 2005 → Jul 2007 | AIDS dysmorphic syndrome | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00084253 Comparator | Jun 2004 → Aug 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00242216 Comparator | May 2004 → Mar 2010 | HIV infectious disease | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT01445223 Comparator | Apr 2004 → Dec 2009 | HIV infectious disease | Göteborg University | Completed | No outcome recorded |
| — | NCT05044962 Comparator | Nov 2021 → Mar 2027 expected | HIV infectious disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| — | NCT00916448 Comparator | May 2009 → Mar 2010 | infectious disease with sepsis, multiple organ dysfunction syndrome | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT02102048 Comparator | Jan 2009 → Mar 2014 | HIV infectious disease | University of Roma La Sapienza | Unknown | No outcome recorded |
| — | NCT00413153 Comparator | May 2006 → Dec 2008 | HIV infectious disease | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00192608 Background | Nov 2004 → May 2006 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 24
| Date | Issuer | Release |
|---|---|---|
| 2017-10-04 | Gilead Sciences | Results Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens gilead.com ↗
In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks. |
| 2017-08-03 | AbbVie | Regulatory AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks abbvie.com ↗
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved MAVYRET™ (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). |
| 2017-05-30 | Gilead Sciences | Results Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies gilead.com ↗ |
| 2016-07-18 | GlaxoSmithKline | Results ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV gsk.com ↗
ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 495 treatment-naïve women living with HIV. |
| 2015-07-21 | Bristol-Myers Squibb | Results Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development bms.com ↗ |
| 2015-07-16 | Bristol-Myers Squibb | Regulatory European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults bms.com ↗
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Commission has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir. |
| 2015-01-29 | Bristol-Myers Squibb | Regulatory U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults bms.com ↗
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. |
| 2014-04-14 | Bristol-Myers Squibb | Regulatory Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1 bms.com ↗
Bristol-Myers Squibb Company (NYSE:BMY) announced today the submission of a new drug application (NDA) on April 4, 2014 to the U.S. Food and Drug Administration (FDA) for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz ®, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. |
| 2014-03-05 | Merck Sharp & Dohme LLC | Results New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1 merck.com ↗
On the other co-primary endpoint of failure due to tolerability, the ISENTRESS and darunavir/r regimens were superior to the atazanavir/r regimen. |
| 2014-03-05 | Bristol-Myers Squibb | Results Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients bms.com ↗
Among HIV-1 infected treatment-experienced patients receiving BMS-663068, 69-80% had HIV-1 RNA levels of < 50 c/mL (a measure indicating virus replication is undetectable), compared to 75% of patients taking Reyataz with ritonavir. |
| 2012-07-24 | Gilead Sciences | Results Gilead’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study gilead.com ↗
The study found that an HIV regimen containing a cobicistat-boosted protease inhibitor was non-inferior to a regimen containing a ritonavir-boosted protease inhibitor at 48 weeks of therapy. |
| 2012-03-06 | Merck Sharp & Dohme LLC | Results Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗
In this study, concomitant administration of VICTRELIS with ritonavir (Norvir ® ) in combination with atazanavir (Reyataz ® ) or darunavir (Prezista ® ), or with lopinavir/ritonavir (Kaletra ® ) resulted in reduced exposures of the HIV medicines and VICTRELIS. |
| 2012-02-08 | Merck Sharp & Dohme LLC | Results Merck Informs U.S. Physicians of Results of Drug Interaction Study of Co-Administration of VICTRELIS™ with Ritonavir-Boosted HIV Protease Inhibitors merck.com ↗
In this study, concomitant administration of VICTRELIS with ritonavir (Norvir®) in combination with atazanavir (Reyataz®) or darunavir (Prezista®),or with lopinavir/ritonavir (Kaletra®) resulted in reduced exposures of the HIV medicines and VICTRELIS. |
| 2011-12-05 | Gilead Sciences | Results Gilead’s Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study gilead.com ↗
Discontinuation rates due to adverse events were 7.3 percent and 7.2 percent in the cobicistat and ritonavir arms of the study, respectively. |
| 2011-03-02 | Vertex Pharmaceuticals Incorporated | Results Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference vrtx.com ↗
Telaprevir slightly increased the exposure to ritonavir-boosted atazanavir. |
| 2011-02-07 | Bristol-Myers Squibb | Regulatory FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women bms.com ↗
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the labeling for REYATAZ ® (atazanavir sulfate) to include dose recommendations in HIV-infected pregnant women. |
| 2010-09-13 | Gilead Sciences | Results Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study gilead.com ↗
Results from a separate study also being presented by Dr. Elion at ICAAC show that cobicistat-boosted atazanavir plus Truvada has similar efficacy and safety to ritonavir-boosted atazanavir plus Truvada at 48 weeks. |
| 2010-01-06 | Gilead Sciences | Results Phase II Clinical Trial of Gilead's Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad" Regimen Meets 24-Week Primary Objective gilead.com ↗
GS 9350-boosted atazanavir and Truvada had similar efficacy to ritonavir-boosted atazanavir and Truvada. |
| 2009-11-05 | Bristol-Myers Squibb | Regulatory FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients bms.com ↗
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ ® to include long-term data from the CASTLE Study. |
| 2008-10-26 | Bristol-Myers Squibb | Results 96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients bms.com ↗
The CASTLE results demonstrated the non-inferiority of REYATAZ/r once daily versus lopinavir/r twice daily, each as part of HIV combination therapy in previously untreated HIV-1 infected adult patients. |
| 2008-10-01 | Bristol-Myers Squibb | Regulatory U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients bms.com ↗ |
| 2008-08-05 | Bristol-Myers Squibb | Results CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender bms.com ↗
CASTLE DATA SHOWED BOOSTED REYATAZ ® (ATAZANAVIR SULFATE) AND LOPINAVIR/R ACHIEVED SIMILAR RESULTS FOR UNDETECTABLE VIRAL LOAD IN TREATMENT-NAIVE HIV-1 INFECTED PATIENTS, REGARDLESS OF GENDER |
| 2008-08-05 | Bristol-Myers Squibb | Results CASTLE Data Showed Boosted REYATAZ® (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender bms.com ↗ |
| 2008-02-06 | Bristol-Myers Squibb | Results CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ® (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients bms.com ↗ |
All press releases naming this drug 30 releases
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 198 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | atazanavir | “Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗182“Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗ “Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted...” NCT01815736 ↗ “Following the washout period, all participants who received TAF in Part 1 and have a \> 0.5 log10 decline in HIV-1 RNA will receive...” NCT01967940 ↗ “ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as...” NCT05044962 ↗ “This 48-week randomized study examined the safety and efficacy of a switch in CART to a once-daily regimen of saquinavir (SQV), ritonavir (RTV), and atazanavir (ATV) that did...” PMID 17479946 ↗ Apr 2007 “Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the...” NCT02397096 ↗ “The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir” NCT00820118 ↗ “Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.” NCT02269917 ↗ “Tenofovir+Emtricitabine+Third agent (Including a ritonavir-boosted protease inhibitor : saquinavir or indinavir or fosamprenavir or tipranavir or darunavir or atazanavir or lopinavir” NCT02302547 ↗ “Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents” NCT02556268 ↗ |
| Known as | Atazanavir (as sulfate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | atazanavir (Reyataz, ATV) | “atazanavir (Reyataz, ATV)” NCT00884793 ↗ |
| Known as | Atazanavir krka | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | Atazanavir mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | Atazanavir so4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | ATAZANAVIR SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | Atazanavir sulfate component of evotaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | Atazanavir Sulphate | “Drug: Atazanavir Sulphate” NCT01335698 ↗1“Drug: Atazanavir Sulphate” NCT00357721 ↗ |
| Known as | Atazanavir viatris (previously atazanavir mylan) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | atazanavir/r | “Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r.” NCT01923311 ↗2“protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r” NCT03256422 ↗ “atazanavir/r” NCT02157311 ↗ |
| Known as | Atazanaviri sulfas | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | Atazor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | ATV | “Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗39“This 48-week randomized study examined the safety and efficacy of a switch in CART to a once-daily regimen of saquinavir (SQV), ritonavir (RTV), and atazanavir (ATV) that did...” PMID 17479946 ↗ Apr 2007 “Concurrent atazanavir (ATV) and lopinavir/ritonavir (LPV/r) may be useful for patients with extensive antiretroviral resistance; however, limited information exists concerning...” PMID 19906626 ↗ Sep 2009 “The purpose of this study is to determine whether two drugs, atazanavir (ATV) and ritonavir (RTV), will control HIV infection when taken together without any other anti-HIV...” NCT00084019 ↗ “We therefore evaluated the PK profiles of lower than the standard doses of atazanavir/ritonavir (ATV/RTV) in 22 adult Thai patients with well-suppressed human immunodeficiency...” PMID 19118378 ↗ Dec 2008 “Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period.” NCT00896051 ↗ “receive abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily.” PMID 19358725 ↗ Apr 2009 “Cobicistat (COBI) enhances atazanavir (ATV) pharmacokinetic parameters similarly to ritonavir (RTV) in both healthy volunteers and HIV-infected adults.” PMID 27774892 ↗ 2017 “To assess safety and efficacy of a switch to unboosted atazanavir (ATV) among HIV-infected adults receiving ATV/ritonavir (r) and tenofovir” PMID 28067119 ↗ Jan 2017 “the antiretroviral drug atazanavir (ATV) increases bilirubin levels but may also increase von Willebrand factor levels.” PMID 29023508 ↗ Oct 2017 “combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects” NCT00814879 ↗ |
| Known as | ATZ | “Step 2 is open label. Regimens include 2 or 3 nucleoside reverse transcriptase inhibitors (NRTIs) in combination with EFV, atazanavir (ATZ), ritonavir-boosted ATZ, or tenofovir...” NCT00013520 ↗3“between danoprevir (DNV) when coadministered with low-dose ritonavir (r) and tenofovir disoproxil fumarate (TDF) or atazanavir (ATZ) in healthy volunteers” NCT01592305 ↗ “A drug-drug interaction between the anti-HIV drugs tenofovir DF (TDF) and atazanavir (ATZ) results in lower ATZ plasma levels” NCT01351740 ↗ “Atazanavir(ATZ) and Tenofovir(TDF)” NCT01368783 ↗ |
| Known as | BMS 232632 | “Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens” NCT00006604 ↗1“Atazanavir (BMS-232632)” NCT00046345 ↗ |
| Known as | BMS-232632-05 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | CGP-73547 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | NSC-742546 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗ |
| Known as | Reyataz | “Atazanavir (Reyataz) was the first protease inhibitor once daily approved in 2003 for the treatment of HIV patients.” NCT02473328 ↗9“Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens” NCT00006604 ↗ “Lamivudine (Epivir, GSK), Atazanavir (Reyataz, BMS), Ritonavir (Norvir, Abbott)” NCT01599364 ↗ “Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)” NCT00355719 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02605954 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02616783 ↗ “Drug: Atazanavir (Reyataz)” NCT00885482 ↗ “atazanavir (Reyataz)” NCT00426296 ↗ |
| Known as | Reyataz (atazanavir) | “Reyataz (atazanavir)” NCT01902186 ↗ |
| Action | Inhibit | “the protease inhibitor (PI) atazanavir (ATV)” NCT00006604 ↗ |
| Modality | Other / unclassified | “ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF” PMID 22748590 ↗ Jun 2012 |
| Route | Oral | “Active Comparator, Capsules, tablets, Oral” NCT00035932 ↗ |
| Target | UGT1A1 | “uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) enzyme pathway.(5).ATV is a known inhibitor of this enzyme pathway” NCT00814879 ↗ |